Literature DB >> 7731874

Frequency analysis of the P wave: comparative techniques.

P Stafford1, P Denbigh, R Vincent.   

Abstract

Frequency domain analysis of the signal-averaged P wave (SAPW) may provide additional information over time domain analysis in patients with paroxysmal atrial fibrillation (PAF), but an optimum method has not yet been defined. We compared two different approaches using SAPW and test signals. We analyzed the frequency spectrum of the entire P wave (method A) or of only its terminal 100 msec (method B) using SAPW from 24 patients with idiopathic PAF and 34 normal controls. Absolute powers in frequency bands above 20, 30, 40, 60, and 80Hz (P20, P30, P40, P60, and P80) and power ratios about these frequencies (PR20, PR30, PR40, PR60, and PR80) were calculated. Patients had greater P30, P60, and P80 using method A (P30: 28.6 [+/- 2.2] vs 22.8 [+/- 1.6] microV2.s; P = 0.04; P60: 4.7 [+/- 0.5] vs 3.4 [+/- 0.3] microV2.s; P = 0.03; P80: 1.9 [+/- 0.2] vs 1.3 [+/- 0.09] microV2.s; P = 0.01) but differences were smaller with method B. Moving the P wave endpoint 10 msec into the P wave had no effect on frequency domain parameters using method A but produced important changes using method B. Both methods were also applied to test signals of different durations but equal powers and power ratios. Method A gave predicted values for power and PR40 at all signal durations, but method B produced variable results. Frequency domain analysis of the SAPW shows significant increases in P wave energy in patients with PAF compared to controls. Analysis of the entire P wave is influenced less by signal duration and variations of the P wave endpoint than analysis of the terminal P wave alone and may define patient and control populations more precisely.

Entities:  

Mesh:

Year:  1995        PMID: 7731874     DOI: 10.1111/j.1540-8159.1995.tb02516.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  7 in total

1.  Noninvasive assessment of atrial substrate change after wide area circumferential ablation: a comparison with segmental pulmonary vein isolation.

Authors:  Damian P Redfearn; Allan C Skanes; Lorne J Gula; Michael J Griffith; Howard J Marshall; Peter J Stafford; Andrew D Krahn; Raymond Yee; George J Klein
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-10       Impact factor: 1.468

2.  Signal averaged P wave compared with standard electrocardiography or echocardiography for prediction of atrial fibrillation after coronary bypass grafting.

Authors:  P J Stafford; S Kolvekar; J Cooper; J Fothergill; F Schlindwein; D P deBono; T J Spyt; C J Garratt
Journal:  Heart       Date:  1997-05       Impact factor: 5.994

3.  Reproducibility of the signal averaged P wave: time and frequency domain analysis.

Authors:  P J Stafford; J Cooper; J Fothergill; F Schlindwein; D P deBono; C J Garratt
Journal:  Heart       Date:  1997-05       Impact factor: 5.994

4.  Atrial fibrillation in end stage renal disease patients: influence of hemodialysis on P wave duration and atrial dimension.

Authors:  S Genovesi; P Fabbrini; F Pieruzzi; E Galbiati; E Sironi; D Pogliani; G Bonforte; M R Viganò; A Stella
Journal:  J Nephrol       Date:  2014-08-14       Impact factor: 3.902

5.  The frequency analysis of signal-averaged ECG of P wave as predictor of efficacy of class III antiarrhythmic drugs to maintain sinus rhythm in recurrent idiopathic atrial fibrillation.

Authors:  E C Barbosa; P R Barbosa; P Ginefra; A de Souza Bomfim; S H Boghossian; P J da Rocha; F M Filho
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-01       Impact factor: 1.468

6.  Effect of low dose sotalol on the signal averaged P wave in patients with paroxysmal atrial fibrillation.

Authors:  P J Stafford; J Cooper; D P de Bono; R Vincent; C J Garratt
Journal:  Br Heart J       Date:  1995-12

7.  Optimal analysis of the signal averaged P wave in patients with paroxysmal atrial fibrillation.

Authors:  P J Stafford; D Robinson; R Vincent
Journal:  Br Heart J       Date:  1995-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.